BioVaxys Sees Manufacturing Partner Reach Bioproduction Milestone For Ovarian Cancer Vaccine

BioVaxys Technology Corp. (CSE: BIOV) announced this morning that its France-based manufacturing partner, Bio Elpida, has reached milestones in its bioproduction process related to the company’s ovarian cancer vaccine.

The partnership is currently working on the biotech firm’s cancer vaccine candidate BVX-0918A. Bio Elpida has recently concluded technology process transfer with BioVaxys and is expected to now focus on developing the manufacturing process.

“This major step is essentially a ‘dry-run’ for manufacturing the vaccine and preparation for GMP (good manufacturing practice) production,” said Bio Elpida President Gilles Devillers.

As the cancer vaccine producer develops the manufacturing approach, the company relayed that the preparation of the new manufacturing facility is also underway.

Following this milestone, the next step is the vaccine process validation using donated tumor samples obtained from ovarian cancer patients.

The ovarian cancer vaccine candidate is also headed for a planned phase 1 trial in Spain with the biotech firm’s EU commercial partner Procare Health Iberia.

BioVaxys Technology last traded at $0.44 on the CSE.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Baselode Energy To Acquire Forum Energy: The Merger Of Equals Deal

TriStar Gold: The Revised Castelo de Sonhos Prefeasibility Study

Gold is Up 30%, But the Real Bull Market is Only Starting Now! | Adrian Day

Recommended

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Goliath Resources Expands 2025 Drill Program To 60,000 Metres

Related News

Market Movers: Canadian Small Cap COVID-19 Stocks Take A Beating

COVID-19 related stocks are all the rage this morning, however it appears to be for...

Monday, November 9, 2020, 10:56:07 AM

BioVaxys Announces Study On Modified Spike Protein In COVID-19 Vaccine To Reduce Risk Of Rare Side Effects

BioVaxys Technology Corp. (CSE: BIOV) announced this morning that it has initiated a study on...

Thursday, September 23, 2021, 11:42:00 AM